tbuckley/cabot-search huggingface dataset:
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Authors: Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O'Brien
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve (TN) or had relapsed/refractory (R/R) CLL after ≥1 prior therapy in a phase Ib/II study (PCYC-1102). Subsequently, the ibrutinib 420 mg dose was approved in CLL. Experimental Design: We report data with 44 months of follow-up on 94 patients with TN and R/R CLL/SLL receiving ibrutinib 420 mg once-daily in PCYC-1102 and the long-term extension study PCYC-1103. Results: Ninety-four CLL/SLL patients (27 TN, 67 R/R) were treated with ibrutinib (420 mg/day). Patients with R/R disease had received a median of four prior therapies (range, 1–12). Responses were rapid and durable and median duration of response was not reached. Best overall response was 91% [85% TN (complete response, CR 26%) and 94% R/R (9% CR)]. Median progression-free survival (PFS) was not reached in either group. The 30-month PFS rate was 96% and 76% for TN and R/R patients, respectively. Ibrutinib was well tolerated with extended follow-up; rates of grade ≥3 cytopenias and fatigue, as well as discontinuations due to toxicities decreased over time. Conclusions: Single-agent ibrutinib at 420 mg once-daily resulted in durable responses and was well tolerated with up to 44 months follow-up in patients with TN and R/R CLL/SLL. Currently, 66% of patients continue on ibrutinib. Clin Cancer Res; 23(5); 1149–55. ©2017 AACR.
Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.
Authors: Jorge Cortes-Franco, Digumarti Raghunadharao, Purvish Parikh, Meir Wetzler, Jeffrey H. Lipton, Dan Jones, Andreas Hochhaus, Hagop M. Kantarjian, Adam R Craig, Annie-Claude Benichou, Eric Humphriss, Franck Emmanuel Nicolini
Journal: Blood (2009)
P3.02c-074 Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
Authors: Francesco Grossi, Erika Rijavec, Federica Biello, Giulia Barletta, Claudia Maggioni, Carlo Genova, Maria Giovanna Dal Bello, Giovanni Rossi, Roberta Distefano, Joanna Roder, Julia Grigorieva, Carlos Oliveira, Maxim Tsypin, Krista Meyer, Heinrich Roder
Journal: Journal of Thoracic Oncology (2017)
M4 Late asthmatic response to epoxy resins: a case report
Authors: E Solano, B Fitzgerald, J Cannon, P Cullinan, J Feary, Ramon y Cajal
Journal: Thorax (2016)

<h3>Introduction</h3> Epoxy resins (ER) systems are used extensively in industry in adhesives, reinforced plastics and surface coatings. ER are converted to the final product by mixing with a “hardener” or curing agent to form a polymer. This process releases fumes which can be respiratory sensitisers and a cause of occupational asthma (OA). <h3>Method</h3> A non-atopic, non-smoker, 41 year old was referred with a six-month history of new onset asthma and 10 month history of nasal congestion and sneezing. His wheeze and dyspnoea occurred in the evenings and improved on holidays. He worked as a materials technician developing bonding agents and had started to use a new ER system one year previously. OA to the ER system was suspected and an in-patient specific inhalational challenge (SIC) performed. On day 1, a pre-treatment solution and a solvent (negative controls) were brushed on to a hard surface for 30 minutes. On day 2, the challenge was repeated using the same methods but with the addition of the ER system used at work. Histamine responsiveness 24 hours post challenge, FEV<sub>1</sub> and symptoms were all monitored. At baseline FEV<sub>1</sub> was 4.3L and bronchial response to histamine was normal (PC 20 16mg/ml). Blinding was not possible due to the patient’s intimate knowledge of the products. <h3>Results</h3> Exposure to the control agents induced no symptoms and no change in FEV<sub>1</sub> or histamine responsiveness. Six hours after the active challenge FEV<sub>1</sub> fell by 16% and the patient reported chest tightness and wheeze. 22 h post-challenge FEV<sub>1</sub> reached a nadir of 2.0 L (52% fall) and bronchodilator therapy was administered (Figure). Histamine responsiveness 24 h post challenge increased with a PC 20 of 3.3 mg/ml. The active challenge was not repeated. <h3>Conclusion</h3> We demonstrated an isolated sustained late asthmatic reaction to the ER system confirming OA. The likely sensitiser was cyclohexylamine (an aliphatic amine hardener) which had a high “Chemical Asthma Hazard Assessment Score” of 0.9283. To ensure patient safety, it is important to be aware of this pattern of response (which is typical of low molecular weight agents). It also explains why the patient did not closely link his symptoms with work. The exact immunological mechanisms are not currently known.
P2.01-039 Prognostic Significance of Claudin Protein Expression in Histological Subtypes of Non-Small Cell Lung Cancer
Authors: Judit Moldvay, Katalin Fabian, Márta Jäckel, Zsuzsanna Németh, Krisztina Bogos, József Furák, László Tiszlavicz, János Fillinger, Zsuzsa Schaff, Balazs Dome
Journal: Journal of Thoracic Oncology (2017)
P3.02c-018 Could COX-2 Inhibitors Enhance the Outcomes of Chemotherapeutic Agents in Lung Cancer?
Authors: Woffgang Hohenforst-Schmidt, Kalliopi Domvri, Paul Zarogoulidis, Nikolaos Zogas, Savvas Petanidis, Efi Kioseoglou, George Zachariadis, Konstantinos Porpodis, Konstantinos Zarogoulidis, Theodor Kontakiotis
Journal: Journal of Thoracic Oncology (2017)
P5 Bloody effusions: do the patient’s clotting results or antithrombotic medications matter?
Authors: L Brockbank, R Pinto, M Gautam
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Current British Thoracic Society Guidelines state that a non-urgent pleural aspiration should be delayed in anti-coagulated patients until the international normalised ratio (INR) is &lt;1.5.<sup>1</sup> There is no specific guidance around the use of antiplatelet/other medications, which may further increase bleeding risk. This creates dilemma for clinicians regarding the best timing of performing pleural procedures to reduce bleeding risk. This study reviewed the potential impact of abnormal clotting results and/or anti-thrombotic medications on the occurrence of blood-stained pleural fluid at aspiration. <h3>Methods</h3> This was a retrospective study, in a large teaching hospital, of all pleural procedures performed between 2013–15, where potential bleeding risk data was available. Diagnostic and therapeutic aspirations as well as intercostal chest drain insertions performed by the Respiratory team were included. An anti-thrombotic medication score for prescribed medications was recorded as follows: aspirin/prophylactic low molecular weight heparin (LMWH) = 1, clopidogrel/ticagrelor = 2, warfarin/therapeutic LMWH = 3, in addition to pre-procedure INR, APTT and platelet count. Pleural effusions were divided into ‘blood-stained’ and ‘non blood-stained’ and the medication score, INR, APTT and platelet count compared between the two groups. <h3>Results</h3> 207 cases were analysed: 73% exudates, 27% transudates. Pleural fluid cytology was available in 77% cases, of which 25% were malignant. The results for the total sample size (n = 207) is shown in the attached table. For blood stained effusions, 33% were malignant vs. non blood stained, 17% malignant. Sub group analysis of malignant and benign effusions showed the same trend for blood stained vs. non blood stained effusions. <h3>Conclusion</h3> Deranged coagulation or prescribed antithrombotics pre-pleural procedure do not appear to significantly increase the likelihood of a obtaining a blood-stained pleural effusion. The aetiology of blood stained pleural effusions is more likely multifactorial and should not always be attributed to a coagulation results or medication related increased bleeding risk. Further study could help determine how to better assess bleeding risk prior to pleural procedures. <h3>Reference</h3> Pleural procedures and thoracic ultrasound: BTS guideline 2010.
Parallel Molecular and Immunological Monitoring of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia (ALL) Patients.
Authors: E.N. Parovichnikova, J.R. Davidyan, I.V. Galtzeva, V.L. Surin, I.A. Vorobiev, E.A. Gretzov, V.G. Isaev, V.G. Savchenko
Journal: Blood (2006)
An Indispensable Role of GM-CSF in the Differentiation of Human Blood Monocytes toward Langerhans Cells.
Authors: Tetsunori Shibasaki, Naoyuki Katayama, Kohshi Ohishi, Fumihiko Monma, Zhaocai Yu, Kazuhiro Nishii, Masahiro Masuya, Hiroshi Shiku
Journal: Blood (2005)
P2.02-049 Gender and Risk of Cessation of Oral Vinorelbine in a Randomized Trial of Concurrent Chemoradiation of Locally Advanced NSCLC
Authors: Olfred Hansen, Tine Schytte, Marianne Knap, Azza Khalil, Christa Nyhus, Tine Mcculloch, Bente Holm, Jon Andersen, Ditte Møller, Tine Nielsen, Lone Hoffmann, Carsten Brink
Journal: Journal of Thoracic Oncology (2017)
The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo
Authors: Melania Capasso, Mandeep K Bhamrah, Robert S Boyd, Kelvin Cain, Karen Pulford, Boris Musset, Vladimir V Cherny, Deri Morgan, Thomas E DeCoursey, Randy D Gascoyne, Martin JS Dyer
Journal: Blood (2008)
P2.01-005 Evaluation of Circulating Tumoral Microemboli (CTM) as a Prognostic Factor in Non-Small Cell Lung Cancer (NSCLC)
Authors: Marcelo Corassa, Marcello Fanelli, Aldo Dettino, Milena Tariki, Emne Abdallah, Alexcia Braun, Vladmir Cordeiro De Lima, Helano Freitas, Ludmilla Chinen
Journal: Journal of Thoracic Oncology (2017)
Mosaic Distribution of RAS Pathway Mutated and Non Mutated Cells in Bone Marrow of Juvenile Myelomonocytic Leukemia.
Authors: Silvia Bresolin, Chiara Frasson, Marco Giordan, Giuseppe Gaipa, Cristina Bugarin, Franco Locatelli, Marco Zecca, Giuseppe Basso, Geertruy Kronnie
Journal: Blood (2012)
P1.01-021 The Impact of Smoking Status on Overall Survival in a Population-Based Non-Small Cell Lung Cancer (NSCLC) Surgical Resection Cohort
Authors: Nicholas Faris, Yu-Sheng Lee, Meghan Meadows, Matthew Smeltzer, Meredith Ray, Kenneth Ward, Carrie Fehnel, Cheryl Houston-Harris, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
P89 Modeling nutritional outcomes for infants diagnosed with cystic fibrosis by newborn screening
Authors: KD Patterson, T Kyriacou, M Desai, WD Carroll, FJ Gilchrist
Journal: Thorax (2016)

<h3>Introduction</h3> Cystic Fibrosis (CF) newborn screening (NBS) was implemented across the UK in 2007. It has been associated with improved clinical outcomes particularly related to nutrition. We reviewed the nutritional progress of infants diagnosed with CF by NBS in the West Midlands. Our aim was to develop a model for predicting height and weight in the first 2 years of life based on information available at the first clinic visit. <h3>Methods</h3> Anthropometric data is recorded at each outpatient visit for children with CF. This data was reviewed in conjunction with the CF NBS data for all children diagnosed with CF in the West Midlands between November 2007 and October 2014. Cluster analysis, classification and polynomial regression modelling were used to analyse these data. Models were validated using the 5-fold cross validation method. <h3>Results</h3> 144 children were identified with CF at a mean age of 22 days. There was no difference in birth weight z scores between pancreatic insufficient and pancreatic sufficient children (−0.05 vs −0.36, p = 0.29) however a significant difference was observed in rate of weight gain from birth to first clinic visit (−0.1 vs −0.33, p = 0.007). Time taken for children to reach a z score of 0 for weight was 65 weeks and length was 90 weeks. Cluster analysis identified two distinct groups of children. Faecal elastase (FE) being the main determinant of class, with a cut off of 212 μg/g. Our models can predict weight z score at 1 and 2 years with a mean absolute error of 0.51 and 0.67 and length z scores at 1 and 2 years with an accuracy of 0.7 and 0.85. The most important factor when predicting future nutritional parameters was birth weight z score. <h3>Conclusions</h3> We have developed and validated models that can provide a good estimate of weight and height z scores in the first 2 years of life for children diagnosed with CF by NBS. These models only require data available at the first clinic visit. They can potentially be used by clinicians to identify children at risk of poor nutritional outcomes thus, encouraging closer monitoring and earlier intervention.
Gene Transfer to Hematopoietic Stem/Progenitor Cells As a Novel Approach for Immunotherapy Against B-Lineage Malignancies: In Vivo Xenograft Model,
Authors: Satiro N. De Oliveira, Francesca Giannoni, Cinnamon Hardee, Arineh Sahaghian, Laurence J N Cooper, Donald B. Kohn
Journal: Blood (2011)
MA12.05 Can Tumor Spread through Air Spaces (STAS) in Lung Adenocarcinomas Be Predicted Pre- and Intraoperatively?
Authors: Koji Kameda, Shaohua Lu, Takashi Eguchi, Natasha Rekhtman, Jason Chang, Joseph Montecalvo, David Jones, William Travis, Prasad Adusumilli
Journal: Journal of Thoracic Oncology (2017)
P66 Falling asleep while driving: is driving safety advice given to patients with excessive daytime sleepiness?
Authors: A Khetarpal, K Anderson, S West
Journal: Thorax (2016)

<h3>Background</h3> 3.5 million people in the UK have excessive daytime sleepiness and 1 in 5 Road Traffic Accidents are due to sleepiness while driving. <h3>Aim</h3> To improve Patient and Public safety by auditing whether DVLA’s driving safety advice is given to patients with excessive daytime sleepiness in two settings: (i) at referral as recommended by The Royal Society for the Prevention of Accidents guidelines and (ii) at the Regional Sleep Clinic as recommended by the BTS guidelines. <h3>Method</h3> Retrospective study between 01/10/15 and 06/01/16 of (i) 100 referral letters to the Regional Sleep Clinic and (ii) 100 sleep clinic letters to patients’ GP. In both cases, patients were included if the letter mentioned ‘Daytime sleepiness’ or if their Epworth Sleepiness Score (ESS) was over 10 (indicating excessive daytime sleepiness). <h3>Results</h3> Only 19% of referral letters from primary and secondary care had documented giving driving safety advice to patients with daytime sleepiness. Sixteen specialties referred patients to the Sleep clinic. General Practice accounted for three quarters of these referrals and driving safety had only been discussed in 14% of cases. Even with specialties like Respiratory medicine and Neurology which see patients with sleep disorders regularly, very few had discussed driving safety. The Sleep Clinic gave DVLA advice to 85% of patients. In the 15% where no advice was given, patients usually had ESS &lt;10 (but symptomatically sleepy) or sleepiness as a secondary consequence of insomnia/non-REM parasomnia. 7 patients reported falling asleep while driving (only 2/7 were discovered at referral). Moreover, the Sleep Clinic noted that 1 had a Road Traffic Accident and 1 had a near miss. Average waiting time from referral to Sleep Clinic appointment was 3 months. Thus driving advice needs to be given at referral. A limitation of this audit is that not all clinicians record discussions about driving even though it is important for medicolegal purposes. <h3>Conclusion</h3> Driving safety discussions on referral can be improved by educating GPs/secondary care and introducing an Alert on eReferral. The Sleep Clinic should use a pro forma to remind clinicians to discuss driving regardless of a patient’s ESS or diagnosis.
P3.02a-023 Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
Authors: Edmond Bendaly, Anand Dalal, Kenneth Culver, Philip Galebach, Iryna Bocharova, Rebekah Foster, Gero Struebbe, Annie Guerin
Journal: Journal of Thoracic Oncology (2017)
P1.02-037 Mutations of EGFR and KRAS Genes in Belorussian Patients With Non-Small Cell Lung Cancer
Authors: Alena Mikhalenka, Anna Shchayuk, Evelina Krupnova, Michael Shapetska, Natalia Chebotaryova, Svetlana Pissarchik
Journal: Journal of Thoracic Oncology (2017)
SUV Max Reduction Criteria of Interim Positron Emission Tomography Improves Prognostic Value in Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Review
Authors: Yusuke Okamoto, Shinichi Ochi, Takashi Nagayama, Shogo Nabe, Kazuya Sakai, Hiroyuki Muranushi, Hiroyuki Sugiura, Kazuya Okada, Aki Sato, Takayuki Sato, Takeshi Maeda, Tatsuhito Onishi, Yasunori Ueda
Journal: Blood (2014)
Retrospective Monocentric Study of Patients with Refractory Hodgkin Lymphoma: Allogeneic Stem Cell Transplantation (alloSCT) Compared to Conventional Treatment Using the Propensity Score Matching Method.
Authors: Helene Labussiere, Matthieu Reshe Rigon, P. Brice, Patricia Ribaud, Vanderson Rocha, Anna Petropoulou, Régis Peffault, Agnès Devergie, Gerard Socie, Marie Robin
Journal: Blood (2009)
Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells
Authors: Olivia Marini, Sara Costa, Dalila Bevilacqua, Federica Calzetti, Nicola Tamassia, Cecilia Spina, Donata De Sabata, Elisa Tinazzi, Claudio Lunardi, Maria T. Scupoli, Chiara Cavallini, Elisa Zoratti, Ilaria Tinazzi, Antonio Marchetta, Aurora Vassanelli, Maurizio Cantini, Giorgio Gandini, Andrea Ruzzenente, Alfredo Guglielmi, Francesco Missale, William Vermi, Cristina Tecchio, Marco A. Cassatella, Patrizia Scapini
Journal: Blood (2017)
P1.01-053 Lung Cancer in Brazil: Men and Women Differences
Authors: Maria Teresa Ruiz Tsukazan, Álvaro Vigo, Vinícius Duval Da Silva, Arthur Vieira, Renata Rosenthal, Flavio Cabral, Gabriel Schwarcke, João Schmitt, Maicon Cimarosti, Jayme Rios, José Antônio Figueiredo Pinto
Journal: Journal of Thoracic Oncology (2017)
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine
Authors: Maria Sullivan, Adam Bisaga, Martina Pavlicova, C. Jean Choi, Kaitlyn Mishlen, Kenneth M. Carpenter, Frances R. Levin, Elias Dakwar, John J. Mariani, Edward V. Nunes
Journal: American Journal of Psychiatry (2017)

At present there is no established optimal approach for transitioning opioid-dependent adults to extended-release injection naltrexone (XR-naltrexone) while preventing relapse. The authors conducted a trial examining the efficacy of two methods of outpatient opioid detoxification for induction to XR-naltrexone.Participants were 150 opioid-dependent adults randomly assigned 2:1 to one of two outpatient detoxification regimens, naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of XR-naltrexone. Naltrexone-assisted detoxification lasted 7 days and included a single day of buprenorphine followed by ascending doses of oral naltrexone along with clonidine and other adjunctive medications. Buprenorphine-assisted detoxification included a 7-day buprenorphine taper followed by a week-long delay before administration of XR-naltrexone, consistent with official prescribing information for XR-naltrexone. Participants from both groups received behavioral therapy focused on medication adherence and a second dose of XR-naltrexone.Compared with participants in the buprenorphine-assisted detoxification condition, participants assigned to naltrexone-assisted detoxification were significantly more likely to be successfully inducted to XR-naltrexone (56.1% compared with 32.7%) and to receive the second injection at week 5 (50.0% compared with 26.9%). Both models adjusted for primary type of opioid use, route of opioid administration, and morphine equivalents at baseline.These results demonstrate the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with single-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid dependence to XR-naltrexone. This strategy offers a promising alternative to the high rates of attrition and relapse currently observed with agonist tapers in both inpatient and outpatient settings.
P172 Demographic factors and temporal patterns affecting treatment success with pirfenidone for patients with idiopathic pulmonary fibrosis?– a large retrospective review
Authors: AD Redfern, N Turner, AC Murphy, FA Woodhead
Journal: Thorax (2016)

<h3>Introduction/objectives</h3> Idiopathic Pulmonary Fibrosis is progressive with poor outcomes. Evidence from the CAPACITY and ASCEND trials suggests Pirfenidone slows disease progression (Noble <i>et al</i>, 2011; King <i>et al</i>, 2014). We reviewed all patients with more than a year since initiation to assess the proportion that discontinued Pirfenidone for adverse drug reactions (ADRs) or due to unsuccessful treatment (&gt;10%/year%FVC decline or died on therapy), to assess temporal patterns of these stoppages and assess any demographic or disease extent predictors of success (age, sex, BMI, smoking history, %FVC prediction and FEV1). <h3>Methods</h3> 155 patients have been referred to our consultant pharmacist for Pirfenidone initiation since August 2013, of which 65 started and have more than 1 year of data (i.e., we excluded those starting post July 2015). We reviewed hospital databases and medical notes with subsequent data analysis using appropriate parametric statistical methods. <h3>Results</h3> 42/65 (64.6%) stopped therapy overall divided between ADRs (24/42, 57.1%), FVC decline &gt;10%/year (11/42, 26.2%), dying on treatment (5/42, 11.9%) and unclear (2/42, 4.8%). Table 1 demonstrates association between demographics and those that discontinued, suggesting there is one subgroup associated with treatment continuation (patient previously smoked P ≤ 0.001). The temporal pattern of stopping treatment for ADRs vs those failing for clinical reasons (death on treatment or FVC decline) demonstrated a median cessation time of 40 days vs 226 respectively. <h3>Conclusions</h3> Our data suggests two important findings. Firstly, patients’ chances of continuing therapy is intriguingly affected positively by smoking history, causation for which remains unclear. Sex, age, BMI or disease extent does not seem to be associated with outcome success. Secondly, those that discontinued for ADRs did so much earlier than those that discontinued due to FVC decline or dying on treatment. Potential implications for when prescribing Pirfenidone are that we cannot predict those at risk of discontinuation from their demographics. However, a smoking history intriguingly seems to be positively associated with continuation. Additionally, most patients affected by ADRs ceased treatment early, suggesting that if side effects are not noted post early follow up, they are unlikely to occur later. This information improves understanding of prescribing practice for Pirfenidone.